15 research outputs found
PROTAC-mediated degradation of Bruton's tyrosine kinase is inhibited by covalent binding
The impact of covalent binding on PROTAC-Mediated degradation of BTK was investigated through the preparation of both covalent binding and reversible binding PROTACs derived from the covalent BTK inhibitor ibrutinib. It was determined that a covalent binding PROTAC inhibited BTK degradation despite evidence of target engagement, while BTK degradation was observed with a reversible binding PROTAC. These observations were consistently found when PROTACs that were able to recruit either IAP or cereblon E3 ligases were employed. Proteomics analysis determined that the use of a covalently bound PROTAC did not result in the degradation of covalently bound targets, while degradation was observed for some reversibly bound targets. This observation highlights the importance of catalysis for successful PROTAC-Mediated degradation and highlights a potential caveat for the use of covalent target binders in PROTAC design
Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors
Chemoproteomics
profiling of kinase inhibitors with kinobeads enables
the assessment of inhibitor potency and selectivity for endogenously
expressed protein kinases in cell lines and tissues. Using a small
panel of targeted covalent inhibitors, we demonstrate the importance
of measuring covalent target binding in live cells. We present a differential
kinobeads profiling strategy for covalent kinase inhibitors where
a compound is added either to live cells or to a cell extract that
enables the comprehensive assessment of inhibitor selectivity for
covalent and noncovalent targets. We found that Acalabrutinib, CC-292,
and Ibrutinib potently and covalently bind TEC family kinases, but
only Ibrutinib also potently binds to BLK. ZAK was identified as a
submicromolar affinity Ibrutinib off-target due to covalent modification
of Cys22. In contrast to Ibrutinib, 5Z-7-Oxozeaenol reacted with Cys150
next to the DFG loop, demonstrating an alternative route to covalent
inactivation of this kinase, e.g., to inhibit canonical TGF-β
dependent processes
1-(Aminomethyl)-Trans-Cyclooct-4-Ene, a New TCO Derivative for Target Visualization and Target Engagement Measurement in Cells
Click probes have enabled a thorough study of drug interactions in relevant disease models. Proper design of the probes, including the choice of the click moiety coupled to the drug, is crucial to ensure good performance and broad application. A new trans-cyclooctene derivative, amTCO, was synthesised using a phthalimide protecting group as a built-in photosensitiser for the cyclooctene isomerization. The 1-(aminomethyl)-trans-cyclooct-4-ene (amTCO) displays a primary amine group that facilitates conjugation with carboxylic acid or hydroxyl-containing compounds. It can help tuning the physical chemical properties of the resulting probes. An amTCO probe targeting indoleamine 2,3-dioxygenase (IDO1) was superior to a TCO variant. The new probe is an effective tool for visualizing IDO1 and measuring the binding affinities of small molecule inhibitors to IDO1 in cells
A Modular Probe Strategy for Drug Localization, Target Identification and Target Occupancy Measurement on Single Cell Level
Late
stage failures of candidate drug molecules are frequently
caused by off-target effects or inefficient target engagement <i>in vivo</i>. In order to address these fundamental challenges
in drug discovery, we developed a modular probe strategy based on
bioorthogonal chemistry that enables the attachment of multiple reporters
to the same probe in cell extracts and live cells. In a systematic
evaluation, we identified the inverse electron demand Diels–Alder
reaction between <i>trans</i>-cyclooctene labeled probe
molecules and tetrazine-tagged reporters to be the most efficient
bioorthogonal reaction for this strategy. Bioorthogonal biotinylation
of the probe allows the identification of drug targets in a chemoproteomics
competition binding assay using quantitative mass spectrometry. Attachment
of a fluorescent reporter enables monitoring of spatial localization
of probes as well as drug-target colocalization studies. Finally,
direct target occupancy of unlabeled drugs can be determined at single
cell resolution by competitive binding with fluorescently labeled
probe molecules. The feasibility of the modular probe strategy is
demonstrated with noncovalent PARP inhibitors
A Modular Probe Strategy for Drug Localization, Target Identification and Target Occupancy Measurement on Single Cell Level
Late
stage failures of candidate drug molecules are frequently
caused by off-target effects or inefficient target engagement <i>in vivo</i>. In order to address these fundamental challenges
in drug discovery, we developed a modular probe strategy based on
bioorthogonal chemistry that enables the attachment of multiple reporters
to the same probe in cell extracts and live cells. In a systematic
evaluation, we identified the inverse electron demand Diels–Alder
reaction between <i>trans</i>-cyclooctene labeled probe
molecules and tetrazine-tagged reporters to be the most efficient
bioorthogonal reaction for this strategy. Bioorthogonal biotinylation
of the probe allows the identification of drug targets in a chemoproteomics
competition binding assay using quantitative mass spectrometry. Attachment
of a fluorescent reporter enables monitoring of spatial localization
of probes as well as drug-target colocalization studies. Finally,
direct target occupancy of unlabeled drugs can be determined at single
cell resolution by competitive binding with fluorescently labeled
probe molecules. The feasibility of the modular probe strategy is
demonstrated with noncovalent PARP inhibitors
A Modular Probe Strategy for Drug Localization, Target Identification and Target Occupancy Measurement on Single Cell Level
Late
stage failures of candidate drug molecules are frequently
caused by off-target effects or inefficient target engagement <i>in vivo</i>. In order to address these fundamental challenges
in drug discovery, we developed a modular probe strategy based on
bioorthogonal chemistry that enables the attachment of multiple reporters
to the same probe in cell extracts and live cells. In a systematic
evaluation, we identified the inverse electron demand Diels–Alder
reaction between <i>trans</i>-cyclooctene labeled probe
molecules and tetrazine-tagged reporters to be the most efficient
bioorthogonal reaction for this strategy. Bioorthogonal biotinylation
of the probe allows the identification of drug targets in a chemoproteomics
competition binding assay using quantitative mass spectrometry. Attachment
of a fluorescent reporter enables monitoring of spatial localization
of probes as well as drug-target colocalization studies. Finally,
direct target occupancy of unlabeled drugs can be determined at single
cell resolution by competitive binding with fluorescently labeled
probe molecules. The feasibility of the modular probe strategy is
demonstrated with noncovalent PARP inhibitors
A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation Applications
Targeted protein degradation is an emerging new strategy for the modulation of intracellular protein levels with applications in chemical biology and drug discovery. One approach to enable this strategy is to redirect the ubiquitin?proteasome system to mark and degrade target proteins of interest (POIs) through the use of proteolysis targeting chimeras (PROTACs). Although great progress has been made in enabling PROTACs as a platform, there are still a limited number of E3 ligases that have been employed for PROTAC design. Herein we report a novel phenotypic screening approach for the identification of E3 ligase binders. The key concept underlying this approach is the high-throughput modification of screening compounds with a chloroalkane moiety to generate HaloPROTACs in situ, which were then evaluated for their ability to degrade a GFP-HaloTag fusion protein in a cellular context. As proof of concept, we demonstrated that we could generate and detect functional HaloPROTACs in situ, using a validated Von Hippel?Lindau (VHL) binder that successfully degraded the GFP-HaloTag fusion protein in living cells. We then used this method to prepare and screen a library of approximately 2000 prospective E3 ligase-recruiting molecules
Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency
BRCA2 is a well-established cancer driver in several human malignancies. While the remarkable success of PARP inhibitors proved the clinical potential of targeting BRCA deficiencies, the emergence of resistance mechanisms underscores the importance of seeking novel Synthetic Lethal (SL) targets for future drug development efforts. In this work, we performed a BRCA2-centric SL screen with a collection of plant-derived compounds from South America. We identified the steroidal alkaloid Solanocapsine as a selective SL inducer, and we were able to substantially increase its potency by deriving multiple analogs. The use of two complementary chemoproteomic approaches led to the identification of the nucleotide salvage pathway enzyme deoxycytidine kinase (dCK) as Solanocapsine’s target responsible for its BRCA2-linked SL induction. Additional confirmatory evidence was obtained by using the highly specific dCK inhibitor (DI-87), which induces SL in multiple BRCA2-deficient and KO contexts. Interestingly, dCK-induced SL is mechanistically different from the one induced by PARP inhibitors. dCK inhibition generates substantially lower levels of DNA damage, and cytotoxic phenotypes are associated exclusively with mitosis, thus suggesting that the fine-tuning of nucleotide supply in mitosis is critical for the survival of BRCA2-deficient cells. Moreover, by using a xenograft model of contralateral tumors, we show that dCK impairment suffices to trigger SL in-vivo. Taken together, our findings unveil dCK as a promising new target for BRCA2-deficient cancers, thus setting the ground for future therapeutic alternatives to PARP inhibitors.Fil: Guantay, Maria Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; ArgentinaFil: Garro, Cintia. Empresa Oncoprecision S.a.u (empresa Oncoprecision S.a.u);Fil: Siri, Sebastian Omar. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; ArgentinaFil: Pansa, Maria Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; ArgentinaFil: Ghidelli Disse, Sonja. Cellzome Gmbh; AlemaniaFil: Paviolo, Natalia Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; ArgentinaFil: Racca, Ana Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; ArgentinaFil: Nicotra, Viviana Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto Multidisciplinario de Biología Vegetal. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas Físicas y Naturales. Instituto Multidisciplinario de Biología Vegetal; ArgentinaFil: Radu, Caius. University of California; Estados UnidosFil: Bocco, Jose Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; ArgentinaFil: Felice, Rosana. Glaxosmithkline Argentina Sociedad Anonima.; ArgentinaFil: Jansson, Keith H.. Glaxonsmithkline; Estados UnidosFil: Remlinger, Katja. Glaxonsmithkline; Estados UnidosFil: Amador, Alejandro. Glaxonsmithkline; Estados UnidosFil: Stronach, Euan. Glaxonsmithkline; Reino UnidoFil: Coleman, Kevin. Glaxosmithkline; Estados UnidosFil: Muelbaier, Marcel. Cellzome Gmbh; AlemaniaFil: Drewes, Gerard. Cellzome Gmbh; AlemaniaFil: Gloger, Isro. Glaxosmithkline Global Health Randd; Reino UnidoFil: Madauss, Kevin. Glaxosmithkline; Estados UnidosFil: García, Manuela Emila. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto Multidisciplinario de Biología Vegetal. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas Físicas y Naturales. Instituto Multidisciplinario de Biología Vegetal; ArgentinaFil: Gottifredi, Vanesa. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; ArgentinaFil: Soria, Gastón. Empresa Oncoprecision S.a.u (empresa Oncoprecision S.a.u)
Interrogating the Druggability of the 2‑Oxoglutarate-Dependent Dioxygenase Target Class by Chemical Proteomics
The 2-oxoglutarate-dependent dioxygenase
target class comprises
around 60 enzymes including several subfamilies with relevance to
human disease, such as the prolyl hydroxylases and the Jumonji-type
lysine demethylases. Current drug discovery approaches are largely
based on small molecule inhibitors targeting the iron/2-oxoglutarate
cofactor binding site. We have devised a chemoproteomics approach
based on a combination of unselective active-site ligands tethered
to beads, enabling affinity capturing of around 40 different dioxygenase
enzymes from human cells. Mass-spectrometry-based quantification of
bead-bound enzymes using a free-ligand competition-binding format
enabled the comprehensive determination of affinities for the cosubstrate
2-oxoglutarate and for oncometabolites such as 2-hydroxyglutarate.
We also profiled a set of representative drug-like inhibitor compounds.
The results indicate that intracellular competition by endogenous
cofactors and high active site similarity present substantial challenges
for drug discovery for this target class